Prioritize patients. Focus treatment on those with the most severe infections and those at highest risk of complications. This targeted approach ensures the most effective use of available supplies.
Explore alternative treatments. Consult with dermatologists or infectious disease specialists to identify suitable antifungal alternatives for each patient. Consider terbinafine or itraconazole as potential options, depending on the specific fungal infection and patient factors.
Implement stricter prescribing guidelines. Healthcare providers should carefully review the necessity of griseofulvin before prescribing, considering less resource-intensive treatment plans first. This includes thorough diagnosis and consideration of alternative therapies.
- Develop clear protocols for prescribing griseofulvin, emphasizing its use only for serious infections where alternatives are unsuitable. Establish a system for tracking griseofulvin prescriptions to monitor usage and anticipate potential future shortages.
Engage in active supply chain management. Pharmacies and healthcare institutions should enhance their inventory management practices. This involves optimizing ordering and stockpiling procedures to minimize disruptions to care.
Work closely with pharmaceutical suppliers to secure consistent griseofulvin supply. Explore potential partnerships with other healthcare facilities to facilitate resource sharing during shortages.
Educate patients. Patients should be informed about the griseofulvin shortage and potential alternative treatments. Clear communication helps patients understand the situation and cooperate with necessary adjustments to their treatment plans.
Promote research and development. Invest in research to develop new antifungal drugs to reduce reliance on griseofulvin and enhance treatment options for fungal infections.
